nach oben

Erschienen in:

01.11.2015 | Original Article

Glasgow prognostic score predicts prognosis for cancer patients in palliative settings: a subanalysis of the Japan–prognostic assessment tools validation (J-ProVal) study

verfasst von: Tomofumi Miura, Yoshihisa Matsumoto, Takashi Hama, Koji Amano, Yo Tei, Ayako Kikuchi, Akihiko Suga, Takayuki Hisanaga, Tatsuhiko Ishihara, Mutsumi Abe, Keisuke Kaneishi, Shohei Kawagoe, Toshiyuki Kuriyama, Takashi Maeda, Ichiro Mori, Nobuhisa Nakajima, Tomohiro Nishi, Hiroki Sakurai, Tatsuya Morita, Hiroya Kinoshita

Erschienen in: Supportive Care in Cancer | Ausgabe 11/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The Glasgow prognostic score (GPS), which uses C-reactive protein and albumin levels, is a good predictor of prognosis in cancer patients undergoing anti-tumor therapy. The objective of this study was to investigate the correlation between GPS and survival among cancer patients in palliative settings, as findings in such populations have not been well described.

Methods

This was a subanalysis of a multicenter, prospective, cohort study in patients who were adults, diagnosed with advanced cancer, and first referred to palliative care service in Japan. Patients who were not receiving anti-tumor therapy and who had undergone laboratory examinations were eligible. Clinical features were analyzed to investigate prognostic factors.

Results

A total of 1160 patients were enrolled (41.6 % female; median age, 72 years). The independent predictors were Eastern Cooperative Oncology Group performance status (ECOG PS) score of 4 (hazard ratio (HR), 1.54), liver metastasis (HR, 1.21), dyspnea (HR, 1.35), edema (HR, 1.25), prognostic performance index (HR, 1.56), neutrophil-lymphocyte ratio (HR, 1.43), and GPS of 2 (HR, 1.36). The sensitivity and specificity for 3-week prognosis of a GPS of 2 were 0.879 and 0.410. Median survival time with GPS of 0, 1, and 2 was 58 days (95 % confidence interval, 48–81), 43 days (37–50), and 21 days (19–24), respectively (log-rank test, p < 0.001).

Conclusion

The GPS was a good prognostic indicator for cancer patients in palliative settings.

Morita T, Tsunoda J, Inoue S, Chihara S (1999) The Palliative Prognostic Index: a scoring system for survival prediction of terminally ill cancer patients. Support Care Cancer 7(3):128–133CrossRefPubMed

Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, Eychmueller S, Glare P, Nabal M, Vigano A, Larkin P, De Conno F, Hanks G, Kaasa S (2005) Prognostic factors in advanced cancer patients: evidence-based clinical recommendations—a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 23(25):6240–6248. doi:10.1200/JCO.2005.06.866 CrossRefPubMed

Lau F, Cloutier-Fisher D, Kuziemsky C, Black F, Downing M, Borycki E, Ho F (2007) A systematic review of prognostic tools for estimating survival time in palliative care. J Palliat Care 23(2):93–112PubMed

McMillan DC (2013) The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev 39(5):534–540. doi:10.1016/j.ctrv.2012.08.003 CrossRefPubMed

Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2004) Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 90(9):1704–1706. doi:10.1038/sj.bjc.6601789 PubMedCentralPubMed

Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O'Reilly DS, Foulis AK, Horgan PG, McMillan DC (2011) A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow inflammation outcome study. Eur J Cancer 47(17):2633–2641. doi:10.1016/j.ejca.2011.03.028 CrossRefPubMed

Jiang X, Hiki N, Nunobe S, Kumagai K, Kubota T, Aikou S, Sano T, Yamaguchi T (2012) Prognostic importance of the inflammation-based Glasgow prognostic score in patients with gastric cancer. Br J Cancer 107(2):275–279. doi:10.1038/bjc.2012.262 PubMedCentralCrossRefPubMed

Hwang JE, Kim HN, Kim DE, Choi HJ, Jung SH, Shim HJ, Bae WK, Hwang EC, Cho SH, Chung IJ (2011) Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer. Bmc Cancer 11:489. doi:10.1186/1471-2407-11-489 PubMedCentralCrossRefPubMed

Pinato DJ, Stebbing J, Ishizuka M, Khan SA, Wasan HS, North BV, Kubota K, Sharma R (2012) A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). J Hepatol 57(5):1013–1020. doi:10.1016/j.jhep.2012.06.022 CrossRefPubMed

10.

Partridge M, Fallon M, Bray C, McMillan D, Brown D, Laird B (2012) Prognostication in advanced cancer: a study examining an inflammation-based score. J Pain Symptom Manag 44(2):161–167. doi:10.1016/j.jpainsymman.2011.08.013 CrossRef

11.

Baba M, Maeda I, Morita T, Hisanaga T, Ishihara T, Iwashita T ea (2014) Independent validation of the modified Prognosis Palliative care Study (PiPS) predictor models throughout three palliative care settings. Journal of Pain and Symptom Management

12.

Stone CA, Tiernan E, Dooley BA (2008) Prospective validation of the Palliative Prognostic Index in patients with cancer. J Pain Symptom Manag 35(6):617–622. doi:10.1016/j.jpainsymman.2007.07.006 CrossRef

13.

Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106(6):dju124. doi:10.1093/jnci/dju124 CrossRefPubMed

14.

MacDonald N (2011) Chronic inflammatory states: their relationship to cancer prognosis and symptoms. J R Coll Phys Edinb 41(3):246–253. doi:10.4997/JRCPE.2011.315 CrossRef

15.

Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Fanelli FR, Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD, Boyce A, Nuckolls G (2008) Cachexia: a new definition. Clin Nutr 27(6):793–799. doi:10.1016/j.clnu.2008.06.013 CrossRefPubMed

16.

Miura T, Mitsunaga S, Ikeda M, Shimizu S, Ohno I, Takahashi H ea (2014) Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels. Pancreas

17.

Mitsunaga S, Ikeda M, Shimizu Y, Ohno I, Fruse J, Inagaki M, Higashi S, Kato H, Terao K, Ochiai A (2013) Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 108(10):2063–2069PubMedCentralCrossRefPubMed

18.

Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC (1990) Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 12(5):1179–1186CrossRefPubMed

19.

Morrone G, Ciliberto G, Oliviero S, Arcone R, Dente L, Content J, Cortese R (1988) Recombinant interleukin 6 regulates the transcriptional activation of a set of human acute phase genes. J Biol Chem 263(25):12554–12558PubMed

20.

Young DP, Kushner I, Samols D (2008) Binding of C/EBPbeta to the C-reactive protein (CRP) promoter in Hep3B cells is associated with transcription of CRP mRNA. J Immunol 181(4):2420–2427CrossRefPubMed

21.

Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA, Houghton AN (1993) Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 72(10):3091–3098CrossRefPubMed

22.

Fearon KC, Falconer JS, Slater C, McMillan DC, Ross JA, Preston T (1998) Albumin synthesis rates are not decreased in hypoalbuminemic cachectic cancer patients with an ongoing acute-phase protein response. Ann Surg 227(2):249–254PubMedCentralCrossRefPubMed

23.

Ballmer PE, Ochsenbein AF, Schutz-Hofmann S (1994) Transcapillary escape rate of albumin positively correlates with plasma albumin concentration in acute but not in chronic inflammatory disease. Metabolism 43(6):697–705CrossRefPubMed

24.

Doweiko JP, Nompleggi DJ (1991) The role of albumin in human physiology and pathophysiology, Part III: albumin and disease states. JPEN J Parenter Enter Nutr 15(4):476–483CrossRef

25.

Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12(5):489–495. doi:10.1016/S1470-2045(10)70218-7 CrossRefPubMed

26.

Wigmore SJ, Plester CE, Richardson RA, Fearon KC (1997) Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer 75(1):106–109PubMedCentralCrossRefPubMed

27.

Fearon K, Arends J, Baracos V (2013) Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol 10(2):90–99. doi:10.1038/nrclinonc.2012.209 CrossRefPubMed

28.

Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, Hara M, Taguchi H, Kimura Y, Kato Y, Asaoku H, Kumagai S, Kodama F, Nakahara H, Hagihara K, Yoshizaki K, Kishimoto T (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106(8):2627–2632. doi:10.1182/blood-2004-12-4602 CrossRefPubMed

Titel: Glasgow prognostic score predicts prognosis for cancer patients in palliative settings: a subanalysis of the Japan–prognostic assessment tools validation (J-ProVal) study
verfasst von: Tomofumi Miura
Yoshihisa Matsumoto
Takashi Hama
Koji Amano
Yo Tei
Ayako Kikuchi
Akihiko Suga
Takayuki Hisanaga
Tatsuhiko Ishihara
Mutsumi Abe
Keisuke Kaneishi
Shohei Kawagoe
Toshiyuki Kuriyama
Takashi Maeda
Ichiro Mori
Nobuhisa Nakajima
Tomohiro Nishi
Hiroki Sakurai
Tatsuya Morita
Hiroya Kinoshita
Publikationsdatum: 01.11.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 11/2015
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-015-2693-x

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Glasgow prognostic score predicts prognosis for cancer patients in palliative settings: a subanalysis of the Japan–prognostic assessment tools validation (J-ProVal) study